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A B ST R AC T 
 
 
Introduction. Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired 
non-malignant hematological disorder which affects the pluripotent 
hematopoietic stem cell. The cause of PNH development is the occurrence of 
somatic mutations in the phosphatidylinositol glycan-A gene which encodes a 
protein necessary for the biosynthesis of glycosylphosphatidylinositol 
anchors. The diagnosis of PNH requires the presence of signs of intravascular 
hemolysis, thrombosis, and (or) bone marrow failure. Case Report. We report 
the case of a 42-year-old female, diagnosed with PNH at the age of 27, whose 
evolution was initially characterized predominantly by hemolytic attacks and 
whose disease pattern evolved towards thromboembolic episodes with the 
advancement of age. Conclusions. Establishing the diagnosis of PNH is a 
difficult task and its management requires teamwork. During the evolution of 
the disease, a PNH patient can acquire supplementary risk factors for 
thrombosis, in addition to the pro-coagulant potential of the disease itself. We 
reported this case to remind physicians that establishing the diagnosis of PNH 
is troublesome, and thus it is questionable whether PNH is a rare disease or 
just underdiagnosed. In this context, in the clinical practice of hematologists 
and other physicians as well, PNH remains a veritable Pandora's box.   
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Paroxysmal nocturnal hemoglobinuria (PNH) is an 
acquired non-malignant hematological disorder which 
affects the pluripotent hematopoietic stem cell. The cause 
of PNH development is the occurrence of somatic 
mutations in the phosphatidylinositol glycan-A (PIGA) 
gene located on the X chromosome (Xp22.1) which 
encodes a protein necessary for the biosynthesis of 
glycosylphosphatidylinositol (GPI) anchors [1-4]. 
Consequently, in PNH there is a deficiency in proteins that 
employ GPI anchors to bind to the surface of blood cells, 
such as decay-accelerating factor (DAF or CD55) and 
membrane inhibitor of reactive lysis (MIRL or CD59). 
These molecules are involved in the inhibition of the 
membrane attack complex (MAC), regulating the action of 
the complement system activated via the alternative 
pathway (Figure 1) [1, 2]. Although all cell lines derived 
from the affected stem cell are deficient in GPI-anchored 
proteins, erythrocytes are more likely to be destroyed by 
complement-mediated lysis since they lack a nucleus [2]. 
 
PNH is characterized by phenotypic mosaicism [4]: 
• the sensitivity of type I clones to complement-
mediated lysis is normal. The expression of MIRL 
(CD59) and DAF (CD55) on the surface of 
erythrocytes is normal. 
• the sensitivity of type II clones to complement-
mediated lysis is 2-4 times higher than normal. These 
cells have a partial deficiency in MIRL and DAF. The 
clinical course of PNH patients whose erythrocytes’ 
phenotype corresponds to type II clones is benign, 
suffering from hemolytic crises only when 
supervening events (infections, trauma etc.) lead to 
the brisk activation of the complement system.  
• the sensitivity of type III clones to complement-
mediated lysis is 15-25 times higher than normal. 
These cells are totally deficient in MIRL and DAF 
and, thus, a higher representation of this clone will 
lead to a severe clinical PNH course. 
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Although PNH is regarded as a rare disease in clinical 
practice, with an estimated incidence of 1-1.5/1.000.000, 
this hematological disease might be underdiagnosed, mainly 
due to its myriad of presenting conditions: anemia and 
related-symptoms, thrombosis, smooth muscle dystonia, 
fatigue, hemoglobinuria due to intravascular hemolysis, 
renal impairment, or pulmonary hypertension [2]. Herein, 
we present the case of a female patient with long-lasting 
PNH, with special emphasis on the onset, evolution, and 
management of this great mimicking disease. 
 
Figure 1.  Activation of the complement system via the alternative pathway. Role of DAF, MIRL and Eculizumab. 
Case Presentation 
We report the case of a 42-year-old female, initially 
diagnosed at 15 years of age in a pediatric unit with Evans 
syndrome, based on the presence of hemolytic anemia 
(Coombs test slightly positive) and thrombocytopenia. The 
patient was treated with prednisone and cyclophosphamide 
pulse-therapy without any response and was subjected to 
splenectomy 12 months after the first hospitalization. At 
the age of 18, the patient was admitted to an Internal 
Medicine unit with abdominal discomfort in the upper right 
quadrant and jaundice. Abdominal ultrasound revealed the 
partial thrombosis of a branch of the portal vein and the 
presence of an accessory spleen. In this context, 
anticoagulation therapy with LMWH and thereafter 
acenocoumarol was prescribed. 
The patient was lost for follow-up for nearly 7 years 
and was admitted at the age of 27 to the Hematology Clinic, 
Fundeni Clinical Institute, Bucharest, Romania, with fever, 
jaundice, severe macrocytic anemia with a pattern of 
hemolysis, slight leukopenia, low haptoglobin, dark urine 
(hemoglobinuria), elevated LDH, low C3 values, negative 
Coombs test, low ferritin and leukocyte alkaline 
phosphatase levels, negative anti-DNAds, anti-Ro/SSA 
and anti-LA/SSB antibodies, positive Ham (Figure 2) and 
sucrose tests, and a positive test for hemosiderinuria (the 
main blood tests results are reported in Table 1). The final 
diagnosis of PNH was established before any blood 
transfusions, based on peripheral blood 
immunophenotyping by flow-cytometry. The flow-
cytometric analysis showed a dominant PNH clone within 
the granulocytes (98% type II), monocytes (98% type II) 
and a minor PNH clone in the red blood cells (7.9% type II 
and 0.8% type III, decreased expression of CD59). 
Concomitantly, the patient was diagnosed with hepatitis C 
and blood tests indicated signs of autoimmunity (positive 
rheumatoid factor and positive antinuclear antibodies).  
 
Figure 2. Representation of the Ham test in the 
workup of PNH. 
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Table 1. Laboratory tests results in our patient at the 
time of the PNH diagnosis. 
Laboratory 
parameters 
PNH case Reference 
values 
Hemoglobin 5 g/dL 11.2-17.5 g/dL 
Mean Corpuscular 
Volume 
114.6 fL 80.0-100.0 fL 





Haptoglobin 0.03 g/L 0.3-2 g/L 
Ferritin 14 ng/mL 20-300 ng/mL 
Leukocyte alkaline 
phosphatase score 
0 10-100  
Lactate 
dehydrogenase 
4007 mmol/L 135-225 
mmol/L 
C3 86 mg/dL 90-180 mg/dL  
 
Until 2019, the patient was treated conservatively 
(blood transfusions and anticoagulants), since eculizumab 
(recombinant humanized monoclonal antibody targeted 
against the complement protein C5) could not be 
prescribed to manage any hemolytic crisis as the drug was 
not available in Romania. The evolution of the patient was 
characterized by hemolytic crises triggered by common 
infections and (or) menses. In June 2019, the patient 
presented to the Neurology Clinic of our hospital with 
dysarthria, paresthesia, and loss of function of the upper 
left limb as signs of a stroke. She had also developed 
obesity and hypertension. 
Computed tomography revealed: 
• spontaneous cortico-subcortical hypodensity with loss 
of grey-white matter differentiation located in the right 
frontal area (compatible with a subacute ischemic 
stroke). 
• small spontaneous hypodense lesion similar in density 
to the cerebrospinal fluid depicted as a craniocaudal 
band in the frontal white matter on the right side 
(possible sequelae lesion). 
• minimal calcified atheromata of the parasellar segment 
of the internal carotid artery and left vertebral artery. 
The patient received LMWH, mannitol, and 
cerebrolysin, followed by co-administration of 
acenocoumarol and LMWH, and was ultimately 
discharged with the recommendation to continue 
acenocoumarol treatment indefinitely. The patient had 
admitted the administration of herbal supplements for 
weight loss and she was advised not to consume such 
products due to a possible interaction with acenocoumarol. 
Also, Doppler echocardiography revealed the presence of 
an atrial septal defect (possible ostium secundum) and 
distal occlusion of the internal carotid artery.  
In July 2019, the patient was hospitalized in our clinic 
for abdominal discomfort and nausea, with normal 
hemoglobin, no clinical or biological signs of a hemolytic 
attack, elevated liver enzymes and elevated amylase and 
lipase. Based on the abdominal ultrasound, the diagnosis of 
chronic cholecystitis with possible involvement of the 
pancreas was established. The patient was treated with 
antibiotics, antispasmodics, and antisecretory medication 
and was discharged with the recommendation of 
laparoscopic cholecystectomy if the symptoms persisted. 
In January 2020, due to the development of pericholecystic 
adhesions, open cholecystectomy was performed and the 
patient was discharged seven days after the surgical 
procedure. 
Soon after the intervention, the patient was admitted to 
the Neurology Clinic of our hospital with left central facial 
paresis, left hemiplegia (0/5 on the Medical Research 
Council scale), and left hemihypesthesia. The examination 
by carotid ultrasound imaging underlined the occlusion of 
the internal right carotid artery. Also, echocardiographic 
examination revealed the presence of a patent foramen 
ovale with a right-to-left shunt. Blood tests revealed the 
presence of lupus anticoagulant and a positive cryoglobulin 
test (++). Screening for thrombophilia was negative. 
Computed tomography was performed, showing an area of 
early sub(acute) ischemia located in the frontoparietal 
region, indicative of a re-infarction in the right frontal area, 
and no signs of hemorrhagic transformation. Magnetic 
resonance imaging also confirmed the presence of bilateral 
supratentorial acute ischemic stroke, especially in the right 
fronto-parietal region, and multiple acute lacunar lesions 
which suggested a possible embolic etiology. 
Discussions 
We have presented the case of a patient with long-
lasting PNH. Although the evolution of PNH in her case 
was typical, the definitive diagnosis was established only 
around the age of 27. The onset of the clinical signs was 
precocious, during adolescence, but was misinterpreted as 
Evans syndrome, i.e., autoimmune hemolytic anemia and 
autoimmune thrombocytopenia, frequently associated with 
systemic lupus erythematosus [5]. Thus, the definitive 
diagnosis of PNH was delayed. However, the development 
of thrombotic complications in unusual sites, namely 
splanchnic thrombosis, should have oriented the clinical 
reasoning towards the correct diagnosis. According to Fan 
et al. (2019), PNH is a risk factor for noncirrhotic 
nonmalignant portal vein thrombosis and Budd-Chiari 
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syndrome. However, myeloproliferative neoplasms and 
mutations in thrombophilia-related genes (factor V Leiden 
G1691A, prothrombin G20210A) comprise the most 
frequent genetic association with the two aforementioned 
conditions [6]. Interestingly, splanchnic thrombosis at a 
young age is not uncommon in PNH, with Ain et al. (2018) 
reporting the occurrence of splanchnic thrombosis in a 
PNH female patient of just 14 years of age, who presented 
to the hospital with abdominal pain, palpitations and 
dyspnea. In her case, blood tests revealed the presence of 
hemolytic anemia and a negative Coombs test, and the final 
diagnosis of PNH was confirmed by flow-cytometry (the 
erythrocytes had lost the expression of CD59) [7].  The 
diagnosis of PNH requires the presence of signs of 
intravascular hemolysis, thrombosis, and (or) bone marrow 
failure. In our case report, the definitive diagnosis was 
established with great difficulty because the presentation 
of these signs was sequential, spanning a time frame of 
approximately 12 years. 
Interestingly, in our case, the pattern of disease changed 
over time. Up to the age of 42, the patient experienced 
numerous hemolytic attacks triggered by supervening 
events (infections, menses etc.) and only one thrombotic 
episode, namely the visceral splanchnic thrombosis 
involving the portal vein. Thereafter, the PNH pattern 
changed from predominantly hemolytic to predominantly 
thrombotic (with recurrent ischemic stroke involving the 
frontal region of the cortex), probably in direct relationship 
with the presence of the patent foramen ovale, occlusion of 
the internal carotid artery, additional cardiovascular risk 
factors (e.g. hypertension, obesity), the positive lupus 
anticoagulant and cryoglobulin test, as well as to the fact 
that the patient had previously undergone splenectomy. 
Patent foramen ovale is a possible cause of cryptogenic 
stroke in young adults, and recurrent ischemic stroke due 
to patent foramen ovale has already been reported in PNH 
patients [8-10]. Moreover, patients who underwent 
splenectomy seem to have a higher incidence of 
thromboembolic events, with portal-splenic mesenteric 
vein thrombosis being the most common finding [11]. Our 
patient associated additional risk factors for thrombosis 
(obesity, hypertension, lupus anticoagulant, 
cryoglobulins), although the screening for thrombophilia 
yielded negative results. Thus, as a take-home message, 
close monitoring of the patient diagnosed with PNH is of 
utmost importance, since ageing also leads to the 
acquisition of new disorders. Also, PNH patients who 
experience thrombosis should be prescribed 
anticoagulation therapy indefinitely [12-14]. The possible 
pathophysiological links explaining the evolution of PNH 
in this case report are depicted in Figure 3. 
 
Figure 3.  Possible pathophysiological links explaining 
the evolution of PNH in our patient. 
The patient would have been an ideal candidate for 
eculizumab, a recombinant humanized monoclonal 
antibody targeted against the complement protein C5, for 
multiple reasons: young age, intermediary-high risk, 
dominant major PNH major clone (type II PNH 
clone >80% within the granulocytes), frequent hemolytic 
attacks, and thrombotic events. However, the drug was 
unavailable in Romania at the time. 
Highlights 
✓ Paroxysmal nocturnal hemoglobinuria (PNH) is an 
acquired non-malignant hematological disorder which 
affects the pluripotent hematopoietic stem cell. 
✓ PNH is characterized by intravascular hemolysis, 
thrombosis, and (or) bone marrow failure. 
✓ Although the clinical picture in PNH is dominated by 
the presence of hemolytic attacks, sometimes the 
pattern of the disease can change towards the 
predominance of thromboembolic episodes. 
Conclusions 
Establishing the diagnosis of PNH is a difficult task and 
its management requires teamwork. During the evolution 
of the disease, a PNH patient can acquire supplementary 
risk factors for thrombosis (obesity, hypertension, 
hypercholesterolemia), in addition to the pro-coagulant 
potential of the disease itself. Thus, the patient should be 
closely monitored. We reported this case to remind 
physicians that establishing the diagnosis of PNH is 
troublesome, and thus it is questionable whether PNH is a 
rare disease or just underdiagnosed. In this context, in the 
clinical practice of hematologists as well as other 
physicians, PNH remains a veritable Pandora's box. 
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Anti-DNAds antibodies, anti-double-stranded 
deoxyribonucleic acid antibodies. 
Anti-Ro/SSA antibodies, anti-Sjögren’s-syndrome-
related antigen A antibodies. 
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Anti-LA/SSB antibodies, anti-Sjögren’s-syndrome-
related antigen B antibodies. 
CD, cluster of differentiation. 
DAF, decay-accelerating factor. 
GPI, glycosylphosphatidylinositol. 
LMWH, low molecular weight heparin. 
MAC, membrane attack complex. 
MIRL, membrane inhibitor of reactive lysis. 
PIGA, phosphatidylinositol glycan-A. 
PNH, paroxysmal nocturnal hemoglobinuria.  
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